October 31, 2023

BioBuzz: Addimmune Prepares to go Public, Initiate Phase Ib HIV Trial

BioBuzz: Be More Connected

View the full Article on:

Addimmune Summary

This article highlights the upcoming IPO for Addimmune, the HIV division of American Gene Technologies. This transition aims to secure funds for a crucial Phase 1b clinical trial, which will evaluate the company’s innovative cell therapy for HIV. The therapy leverages genetically modified cells to target the virus directly.

Addimmune is encouraged by promising results from an earlier trial. In this trial, all participants demonstrated a safe immune response, with significant viral suppression observed in several patients. These results suggest that the therapy has the potential to be a significant step toward a functional cure for HIV. We are excited to embark on this new phase and are confident that with the support of our upcoming IPO, we will continue to advance the science of HIV treatment, with the ultimate goal of offering a long-term solution for those living with the virus.